AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VECTUS BIOSYSTEMS LTD

0.145

-0.010-6.45%

Volume:82.37K

Turnover:11.14K

Market Cap:7.74M

PE:-4.34

High:0.145

Open:0.135

Low:0.135

Close:0.155

52wk High:0.455

52wk Low:0.037

Shares:53.41M

Float Shares:22.25M

Volume Ratio:1.17

T/O Rate:0.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.033

EPS(LYR):-0.033

ROE:-289.05%

ROA:-75.73%

PB:-30.18

PE(LYR):-4.34

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

XORTX verlängert Frist für Übernahme des Renal Anti-Fibrotic Therapeutic Program von Vectus bis 31. März 2026

XORTX Awaits ASX Approval to Close Acquisition of Renal Anti-Fibrotic Program from Vectus

XORTX Awaits ASX Decision on Closing Vectus Renal Program Acquisition

Vectus Biosystems Ltd-Quarterly Activities & Appendix 4C Cash Flow Reports

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/VBS.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VBS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"VBS.AU\",,,,,undefined,":{"symbol":"VBS.AU","market":"AU","secType":"STK","nameCN":"VECTUS BIOSYSTEMS LTD","latestPrice":0.145,"timestamp":1770786720000,"preClose":0.155,"halted":0,"volume":82371,"delay":0,"changeRate":-0.06451612903225812,"nameEN":"VECTUS BIOSYSTEMS LTD","floatShares":22254159,"shares":53408331,"eps":-0.0334,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"02-11 16:12:00 AEDT","open":0.135,"high":0.145,"low":0.135,"amount":11143,"amplitude":0.064516,"askPrice":0.155,"askSize":9526,"bidPrice":0.13,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-0.0334,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.155,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":1.1718503252620662,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"VBS.AU\",,,,,undefined,":{"symbol":"VBS.AU","floatShares":22254159,"roa":"-75.73%","roe":"-289.05%","lyrEps":-0.033375,"volumeRatio":1.1718503252620662,"shares":53408331,"dividePrice":0,"high":0.145,"amplitude":0.064516,"preClose":0.155,"low":0.135,"week52Low":0.037,"pbRate":"-30.18","psRate":"16.20","week52High":0.455,"institutionHeld":0,"latestPrice":0.145,"committee":0.679938,"eps":-0.0334,"divideRate":0,"volume":82371,"delay":0,"ttmEps":-0.0334,"open":0.135,"prevYearClose":0.18,"prevWeekClose":0.14,"prevMonthClose":0.14,"prevQuarterClose":0.18,"fiveDayClose":0.115,"twentyDayClose":0.13,"sixtyDayClose":0.28},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VBS.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VBS.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VBS.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609311747","title":"XORTX verlängert Frist für Übernahme des Renal Anti-Fibrotic Therapeutic Program von Vectus bis 31. März 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609311747","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609311747?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:00","pubTimestamp":1770246015,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL67SQxV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","BK7067","VBS.AU","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","BK4588"],"gpt_icon":0},{"id":"2600060305","title":"XORTX Awaits ASX Approval to Close Acquisition of Renal Anti-Fibrotic Program from Vectus","url":"https://stock-news.laohu8.com/highlight/detail?id=2600060305","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600060305?lang=en_us&edition=fundamental","pubTime":"2026-01-03 03:38","pubTimestamp":1767382685,"startTime":"0","endTime":"0","summary":"XORTX Therapeutics Inc. provided an update on the timing for closing its acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited. Vectus is currently awaiting a decision from the Australian Securities Exchange regarding the need for shareholder approval for the sale of the VB4-P5 intellectual property. According to the binding term sheet between XORTX and Vectus, the closing is scheduled to occur no later than January 13, 2026. Both companies remain committed to finalizing the acquisition and will provide further updates once clarity on approval is received.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLbDfWwV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VBS.AU","BK7067"],"gpt_icon":0},{"id":"2600029347","title":"XORTX Awaits ASX Decision on Closing Vectus Renal Program Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2600029347","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600029347?lang=en_us&edition=fundamental","pubTime":"2026-01-01 07:15","pubTimestamp":1767222920,"startTime":"0","endTime":"0","summary":"XORTX Therapeutics Inc. has provided an update on the timing for closing its planned acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, an Australian company listed on the ASX. Vectus is currently awaiting clarification from the ASX regarding whether shareholder approval is required for the sale of the VB4-P5 intellectual property. According to the binding term sheet between XORTX and Vectus, closing is scheduled to occur no later than 90 days after signing, which is January 13, 2026. Both companies remain committed to finalizing the acquisition and will provide additional updates once there is clarity on the ASX approval process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL44qPzP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4585","VBS.AU","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2579662196","title":"Vectus Biosystems Ltd-Quarterly Activities & Appendix 4C Cash Flow Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2579662196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579662196?lang=en_us&edition=fundamental","pubTime":"2025-10-30 15:28","pubTimestamp":1761809287,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUECGCMZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","VBS.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/VBS.AU\",params:#limit:6,delay:true,,,undefined,":[]}}